Bank of America
GEVA

Bank of America’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Bank of America’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-2,746
Closed -$268K – 7638
2015
Q1 		$268K Sell
2,746
-62
-2% -$6.56K ﹤0.01% 4740
2014
Q4 		$261K Sell
2,808
-153
-5% -$12.1K ﹤0.01% 5153
2014
Q3 		$204K Buy
2,961
+2,226
+303% +$159K ﹤0.01% 5372
2014
Q2 		$77K Sell
735
-4,944
-87% -$421K ﹤0.01% 6341
2014
Q1 		$471K Buy
5,679
+4,492
+378% +$415K ﹤0.01% 4655
2013
Q4 		$77K Buy
1,187
+428
+56% +$25.4K ﹤0.01% 6308
2013
Q3 		$48K Sell
759
-10,704
-93% -$527K ﹤0.01% 6451
2013
Q2 		$481K Buy
+11,463
New +$522K ﹤0.01% 4784

Bank of America's GEVA Position: Q2 2015 in Review

Bank of America sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 2,746 shares — an estimated $268K sold.

Bank of America first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $481K in Q2 2013. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • Bank of America reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Bank of America sold 2,746 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $268K.
  • Bank of America first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • Bank of America's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $481K in Q2 2013.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Bank of America's 13F filing for Q2 2015, filed 14 Aug 2015.